Health Economics, Management and Policy Department, Virtual School of Medical Education & Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
PLoS One. 2022 Jun 16;17(6):e0268774. doi: 10.1371/journal.pone.0268774. eCollection 2022.
Respiratory distress is known as one of the leading causes of neonatal death. In recent decades, surfactant therapy has revolutionized respiratory failure. Since the implementation of the health system reform plan as well as the allocation of new financial resources for health system in Iran, the rate of irrational prescription has increased and prescription of surfactant for neonates, has raised unexpectedly, which is thought to be due to irrational prescriptions partly. The present study aimed to determine the rate of irrational prescription of surfactant for neonates with respiratory distress.
This research was a cross-sectional descriptive study, which was conducted retrospectively. In the current study, determining the rate of irrational prescription was done in terms of the surfactant prescription guideline. Finally, the medical data of 846 neonates who underwent surfactant therapy in Iran in 2018, were extracted from the information system of the Ministry of Health and the neonatal medical records.
The results show that drug selection index, dose index, and time index were irrational for 14.30%, 27.42%, and 1.06% of neonates, respectively. Moreover, the total index of drug prescription, which is a combination of the above-mentioned three components, was found to be irrational for 31.47% of neonates.
The results of the present study are considered as a warning to providers and decision makers in the field of neonatal health to reduce irrational prescriptions of surfactant for neonates. This study suggests the use of educational interventions in order to reduce irrational prescriptions due to drug selection as well as the use of computer alert approaches in order to reduce irrational prescriptions due to wrong dose.
呼吸窘迫是新生儿死亡的主要原因之一。近几十年来,表面活性剂治疗使呼吸衰竭的治疗发生了革命性变化。自伊朗实施医疗体制改革计划并为医疗体制分配新的财政资源以来,不合理处方的比例有所增加,新生儿表面活性剂的处方也出人意料地增加,这部分被认为是不合理处方的原因。本研究旨在确定呼吸窘迫新生儿不合理使用表面活性剂的比例。
本研究为回顾性横断面描述性研究。在本研究中,根据表面活性剂处方指南确定不合理处方的比例。最后,从卫生部信息系统和新生儿病历中提取了 2018 年在伊朗接受表面活性剂治疗的 846 名新生儿的医疗数据。
结果表明,药物选择指数、剂量指数和时间指数分别对 14.30%、27.42%和 1.06%的新生儿不合理,此外,上述三个组成部分的药物联合处方总指数对 31.47%的新生儿不合理。
本研究结果被认为是对新生儿保健领域的提供者和决策者的一个警告,以减少新生儿不合理使用表面活性剂。本研究建议采取教育干预措施,减少因药物选择不当而导致的不合理处方,以及采取计算机报警方法,减少因剂量错误而导致的不合理处方。